Showing posts with label lung cancer. Show all posts
Showing posts with label lung cancer. Show all posts

Thursday, December 4, 2014

Lung cancer gets much less research funding than other cancers, but is deadlier, especially in Kentucky

Lung cancer takes more lives annually than breast, prostate, and colon cancers combined, but the disease "generally doesn't get the public attention or research dollars in proportion to its lethality," Arielle Densen, co-founder of Lung Cancer Free World, writes for CNN.

Lung cancer receives $1,442 in federal research funds per death, compared with $26,398 for breast cancer (lung cancer kills nearly twice as many women as breast cancer) and $13,419 for prostate cancer according to a National Institutes of Health study. Funding by private donations increases the gap even further, she writes.

And though lung cancer is usually thought of as a "smokers disease" and often comes with a stigma attached, "the majority of those diagnosed with lung cancer are former smokers or have never smoked at all," Densen writes.

Densen shares the story of her mother, who was diagnosed with lung cancer but had never smoked. Her mom, being a non-smoker and generally "healthy," was told she had pneumonia despite a "lingering, months-long cough." Because she wasn't a smoker it "didn't trigger any red flags." Eventually, a CT scan found a mass in her lung. She was told she had stage 4 lung cancer and had one year to live. But "thanks to advancements in targeted therapies" she lived for 40 months after the diagnosis. She was 59 when she died.

Lung cancer is especially deadly because it usually doesn't cause symptoms until it's already spread to other parts of the body. Kentucky has more cases of lung cancer than any other state, and its lung cancer mortality rate is nearly 50 percent higher than the national average.

The five-year survival rate for lung cancer is around 16 percent and has been for decades and the survival rate for a stage 4 cancer is 4 percent, Densen reports.

Friday, November 14, 2014

Medicare plans to pay for lung-cancer screening, a boon to Ky.

The Centers for Medicare and Medicaid Services plan to start paying for lung cancer screening with low-dose CT scans for people at high risk.

Spiral CT (computed tomography), which is used to look for lung cancer, is a low-dose form of X-ray that delivers about the same radiation as a mammogram, Maggie Fox reports for NBC News.

“I think after a long effort to get to this point, CMS got it right,” Laurie Fenton Ambrose, president and CEO of the Lung Cancer Alliance, told Fox. “This has the potential of being one of the most significant cancer mortality-reducing efforts to date. We are finally focusing on what is a quarter of all cancer, and that’s lung cancer.”

Fox reports, "Experts project that the screening test, which costs $250-$300, may prevent as many as 20 percent of future deaths from lung cancer, making it akin to mammograms and colonoscopies in terms of saving lives."

The proposal covers people aged 55-74 who have smoked at least a pack a day for 30 years, or the equivalent. It is now open for a 30-day comment period.

Lung cancer is especially deadly because it usually doesn’t cause symptoms until it’s already spread to other parts of the body. Kentucky has more cases of lung cancer than any other state, and its lung cancer mortality rate is nearly 50 percent higher than the national average. This year alone, 3,500 Kentuckians will die from lung cancer. Nationally, it kills nearly 160,000 people a year, according to the American Cancer Society.

Concerns about using CT scans to screen for ling cancer are that it isn't cheap, it isn't harmless, and the scans aren't always clear, often causing patients to endure further needless testing, Fox reports: "The national lung screening trial showed that for every five to six lives saved by screening, one person died because of procedures done after screening, including surgery and biopsies that collapsed the lung."

That calls for caution. “We strongly advise older current and former heavy smokers to speak with their doctors about whether CT lung cancer screening is right for them,” Dr. Ella Kazerooni, chair of the American College of Radiology Lung Cancer Screening Committee, told Fox. “If they and their doctor decide that screening is warranted, we encourage patients to seek out an ACR lung cancer screening center.” 

Thursday, November 13, 2014

Kentucky gets a $7 million grant to improve survival rates for lung cancer, in which it leads the nation

The University of Kentucky, the University of Louisville and the Lung Cancer Alliance have joined in a unique project called Kentucky LEADS (Lung Cancer, Education, Awareness, Detection, Survivorship) Collaborative to assess new approaches for identifying lung cancer earlier to improve survival rates.

These efforts are supported through a $7 million grant from the Bristol-Myers Squibb Foundation’s Bridging Cancer Care initiative.

Kentucky has more cases of lung cancer than any other state and its lung cancer mortality rate is nearly 50 percent higher than the national average. This year alone, 3,500 Kentuckians will die from lung cancer, a UK news release reports.

“As Kentucky leads the nation in lung cancer mortality rates, we must step up to be a leader in finding solutions toward preventing, curing and coping with this destructive disease,” Gov. Steve Beshear said. “I strongly support this collaborative, wide-ranging effort as it coincides with this administration’s KyHealthNow goals of reducing statewide cancer and smoking rates by 10 percent by 2019. By working together, we can and will find a way to diminish the burden of this crisis in Kentucky."

The project will also develop and evaluate interventions to improve quality of life and survivorship for individuals with lung cancer and their caregivers, the release says.

"Historically there's not been a lot of research or effort put into lung-cancer survivorship because, unfortunately, there hasn't been much survivorship," said Jamie Studts, associate professor of behavioral science at UK and director of the Kentucky LEADS Collaborative.

One in two patients diagnosed with lung cancer will die within a year. After five years, only 16 in 100 patients will be alive, UKNow writes.

"Those are sobering statistics,” said John Damonti, president of the Bristol-Myers Squibb Foundation. “The timing of diagnosis is critical. Patients diagnosed at Stage 1 have a 57 percent chance of achieving five-year survival. That drops to 4 percent when patients have a late-stage diagnosis. Early detection and treatment of lung cancer, combined with education and patient support, is key to increased survival for patients living with lung cancer.”

The project will include several components: a review of how physicians treat and refer lung cancer patients across the state; the creation of a sustainable lung cancer-specific survivorship program; and a program that will promote evidence-based prevention and early detection of lung cancer in Kentucky.

Early detection has recently become more attainable because lung cancer screening guidelines have recently changed, allowing Kentucky to implement rigorous, statewide screening programs that can save lives, UKNow writes. And because symptoms of lung cancer usually show up after the disease has spread, early screening is critical to reduce deaths.

Tuesday, September 23, 2014

McConnell seeks 'timely and fair review' of plan for Medicare coverage of CT scans for those at high risk for lung cancer

U.S. Sen. Mitch McConnell asked Centers for Medicare and Medicaid Services Administrator Marilyn Tavenner to "give a timely and fair review to determine whether low-dose computerized tomography (CT) scans should be covered by Medicare for patients at high-risk for developing lung cancer," a press release form his office said.

"Lung cancer has the highest mortality rate of all cancers in the United States," Mconnell said. "Additionally, my home state of Kentucky has the highest state mortality rate of lung cancer in the country, and the disease claims the lives of approximately 3,000 Kentuckians every year."

CT scans should be used to detect lung cancer early in individuals who who have a high risk for the disease, the U.S. Preventive Services Task Force recommends. High-risk individuals are those between 55 and 80 who have smoked a pack of cigarettes each day for 30 or more days. The task force noted a significant reduction in deaths from the disease as a result of early detection through CT scans. (Read more)

Thursday, September 4, 2014

UK cancer-center director urges lawmakers to raise cigarette tax and pass a statewide smoking ban to reduce cancer deaths

The Markey Cancer Center at the University of Kentucky supports a statewide smoking ban and an increase in the state cigarette tax to significantly reduce cancer deaths in the state, the center's director told a legislative committee Sept. 3.

“We are highly supportive, and we hope that you will be supportive as well, of (these) initiatives that we think will improve the overall health of Kentuckians,” Dr. B. Mark Evers told the state legislative Tobacco Settlement Agreement Fund Oversight Committee.

A news release from the Legislative Research Commission said Evers presented the numbers to back up his advice: Kentucky is first nationally in percentage of people who get cancer, and in overall cancer mortality. Lung cancer alone accounts for about 35 percent of Kentucky cancer deaths; nationally, lung cancer's share is 28 percent.

Twenty-eight percent of adult Kentuckians smoke, with approximately 8,000 deaths each year from smoking-related illnesses. The greatest incidence of tobacco-related cancers is in Eastern Kentucky.

That is the highest percentage in the U.S., Evers notes, adding that there is an indirect relationship between cigarette taxes and smoking rates. Kentucky has the 12th lowest cigarette tax among the states.

"Raising the cost of cigarettes and a statewide smoking ban could help cut Kentucky cancer deaths by 50 percent," Evers said. That is the Markey Cancer Center's goal over the next five years.

The center has a new strategic plan, "Conquering Cancer in the Commonwealth," that focuses on the state's "major cancer killers" -- lung, head and neck, colorectal, breast, and cervical cancer.

In response to a question about how to decrease the number of smokers in Kentucky, Evers pointed to local smoke-free policies and increased efforts in Appalachia toward smoking cessation.

When asked what it will take to lower the percentage of Kentucky smokers to less than 10 percent, Evers recommended three things: increasing the cigarette excise tax, a statewide smoking ban, and instituting lung-cancer screening projects like those in place at UK and the University of Louisville.

“Those three things are really going to help drive down those numbers,” he said.

Friday, August 22, 2014

Owensboro commissioners drop pre-existing bars from draft of smoking-ban ordinance

The Owensboro City Commission compromised to gain the support of all five members to vote for a smoking ban, which will come up for a vote on Sept. 2, Steve Vied reports for the Owensboro Messenger-Inquirer.

The original draft of the ordinance eliminated smoking in all public places in the city, and was favored narrowly. The compromise allows smoking to continue in establishments that are already in operation and don't allow entry to anyone under 18, thus exempting bars, as a county ordinance does.

"New bars that open after the ordinance goes into effect, whether they allow customers under 18 or not, will not be permitted to have smoking," Mayor Ron Payne said.

"Thank you so much," said Ashley Oberst, an employee of Rocky's Bar and Grill at Ninth and Crittenden streets. "It means more than you know."

"I'm not here to make choices for adults," Commissioner Jeff Sanford said, but if smoking "is around kids, I can't support it."

Payne told the audience at a meeting, "First and foremost, this commission wants to act in unison. We did not want a split vote. No. 2, we have listened to you. You made some good points that we have considered. We all have wrestled with this. This is a toughie. I have three younger brothers, all gone, two from lung cancer."

The new version also deleted regulation of electronic cigarettes. (Read more; this article is behind a paywall)

Monday, June 2, 2014

Breakthrough drugs for targeted diseases work wonders, but are very expensive; some see a trend to worry about

Drugs focusing on narrow subsets of broader diseases are now being developed for individuals with specific genetic makeups. This trend prompts questions about who covers the cost, who gets the drugs and which diseases get the investment dollars, Brady Dennis reports for The Washington Post.

The newest "breakthrough" pharmaceutical is a new lung cancer drug named Zykadia, Dennis reports. The Food and Drug Administration released it four months ahead of schedule.

This drug is not designed to treat everyone who has lung cancer, which kills an estimated 160,000 Americans each year, including 3,500 Kentuckians. Kentucky's lung cancer death rate is almost 50 percent higher than the U.S. rate, placing Kentucky first in the nation for new cases and deaths from lung cancer.

Zykadia is designed to treat only about 5 percent of patients who fit into a specific subset of the disease: those who have advanced, non-small-cell lung cancer, and a specific gene mutation that causes tumors to resist other treatment, Dennis writes. For them—and only them—the drug has the proven potential to shrink tumors and extend lives.

“It’s a new world,” Wendy Selig, president of the Melanoma Research Alliance, told Dennis. “We’re segmenting what we thought of as large diseases into smaller populations of patients that are defined by genetic distinctions. . . . The goal is to match the right therapy to the right patient and to do it with minimal collateral damage.”

Since 2011, the FDA has approved numerous new treatments for melanoma, or skin-cancer patients with certain types of genetic mutations, specific cancers and a small proportion of people with cystic fibrosis, Dennis notes.

The FDA told Dennis that almost 40 of the nearly 50 drugs it has designated as potential “breakthroughs” involve targeted therapies. These targeted therapies often offer recipients earlier and better diagnoses, more effective treatments and even possible cures—or at least more time—for people who previously had little hope.

"But the trend toward targeted medicine also is forcing hard questions on regulators, drug makers, insurers and patients alike: Who should pay for the growing number of specialized drugs, which can cost hundreds of thousands of dollars a year? How does society ensure that everyone who might benefit—rich or poor—can receive treatment? What about patients whose specific conditions or mutations have not attracted investment dollars or the attention of researchers, leaving them to watch and hope from the sidelines?" Dennis writes.

Private insurers and Medicare generally cover the high drug costs, which currently account for only a fraction of overall health-care spending, Dennis reports.

But Barry Werth, an author and journalist who has spent decades writing about the pharmaceutical industry, asks, "What happens when targeted drugs become the rule rather than the exception? Will insurers refuse to cover some of them? Will the government ponder rationing them? Will only the wealthy be able to afford the best and newest treatments?"

This scenario could be happening with Sovaldi, a "groundbreaking new treatment" for the estimated 3 million Americans infected with hepatitis C, Dennis reports. Insurers are publicly rebelling against the drug's price of $1,000 per pill, or $84,000 for a 12-week treatment.

"The worry is that Sovaldi is the poster child for a “tsunami of expensive medicines” that collectively threaten to bankrupt the health-care system," John Rother, president of the National Coalition on Health Care, which represents insurers, employers, consumer and religious groups, health-care providers and some drug manufacturers, told Dennis.

“We’ve been able to absorb it so far because there are very few of them and because they are consumed by very small numbers of people,” Rother said of specialty drugs. “[But] if they’re all priced at the same level Sovaldi is, we really won’t be able to absorb it in the current system. It’s not sustainable.”

Edward Abrahams, president of the Personalized Medicine Coalition, an advocacy organization that includes drug makers, medical providers and patient and research groups, told Dennis that the cost of creating targeted drugs cost billions of dollars and often takes a decade or more to develop. Without the ability to recoup those costs, he said, "research will wither."

“As a society, we’re schizophrenic about this,” Abrahams told Dennis, adding that everyone wants to cure cancer and other diseases. “But at the other end, you have to be willing to pay for these products. . . . When you develop a drug for a segmented population, the cost of that drug is likely to be higher than if it worked for everybody.”

Saturday, May 31, 2014

Smoking increases risk of getting lung cancer by up to 20%, but add other carcinogens and it can go up as much as 300%

If you smoke, your risk of getting lung cancer is as much as 20 times greater than if you don't. But if you smoke and are exposed to other carcinogens such as radon, asbestos, arsenic or chromium, your risk could be 300 times greater, according to "a growing body of research, including two studies under way at the University of Kentucky," reports Laura Ungar of The Courier-Journal.

See below for example of how to use interactive version of map
"The studies help explain why Kentucky’s lung-cancer and death rates are so much higher than for the rest of the nation," Ungar writes, citing experts. The state leads the nation in lung cancer, "and some Appalachian counties’ rates are more than double the national average. While Kentucky’s adult smoking rate of 28 percent is the highest in the nation, it’s not enough to account for the state’s sky-high lung-cancer rates."

Here are two possible causes: Appalachian counties are high in arsenic and chromium, and Central Kentucky has high potential for radon gas, which can accumulate under buildings. "The National Cancer Institute says radon by itself is the second-leading cause of lung cancer in the United States, and most radon-related deaths occur among smokers," Ungar notes. "Kentucky has no laws requiring radon testing for single- or multi-family homes, schools or businesses; and no laws mandating radon-resistant construction of new homes," according to Ellen Hahn, a UK professor of nursing and public health.

"While doctors aren’t sure how smoking interacts with such carcinogens in the body," Ungar writes, "some theorize that when smoking damages lung cells’ DNA, the lungs become more susceptible to damage from other toxins." (Read more) The map above is interactive on the Kentucky Cancer Registry website. Here's an example of how to display county data, which also shows the beginning of the county list ranked by lung-cancer rate; a map of county lung cancer death rates is also available:

UK researchers work to improve identification of lung cancer patients eligible for participation in clinical trials for new treatments

At the University of Kentucky, researchers are developing better strategies to identify lung cancer patients who could participate in clinical trials for new treatments. Lung cancer causes more deaths than any other kind of cancer worldwide, and Kentucky's rates of lung cancer and mortality are the highest in the nation.

Unfortunately, fewer than 1 percent of lung cancer patients participate in clinical trials in part because identifying and recruiting eligible participants is difficult and time-consuming, Mallory Powell writes for UK. The disease is often diagnosed so late that there is little time for clinical trials.

"The combination of the burden of lung cancer in Kentucky and the urgency of identifying patients who are eligible for clinical trials motivated Dr. Eric Durben and his team to devise a more efficient method for screening patient eligibility," Powell writes. Durben is director of the Cancer Research Informatics Shared Resource Facility at UK's Markey Cancer Center and an assistant professor in the division of biomedical informatics in the College of Public Health.

Durbin and his team are using unique electronic data sources managed by UK's Center for Clinical and Translational Science, the Institute for Pharmaceutical Outcomes and Policy, the Markey Cancer Center and the Kentucky Cancer Registry to create system system to identify patients who for clinical trials. The two-year project is in its seventh month.

"Clinical trial recruitment is critically important to the Markey Cancer Center if we're going to get lifesaving therapeutics to our patients," said Dr. Susanne Arnold, associate professor in medical oncology and radiation medicine at Markey. "It's also how we make progress in cancer treatment."

While the project is geared toward lung cancer, its results could address other cancers. "What's really exciting about Dr. Durbin's study is that it has the potential to greatly improve clinical research not only in the lung cancer but in other cancers and disease conditions as well," said Dr. Nathan Vanderford, assistant director for research at Markey. (Read more)